• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 25 of 100
CommentaryWorld leaders should acknowledge that IP protections facilitate vaccine access
By Andrei IancuDecember 24, 2021
HealthAstraZeneca finds its COVID booster delivers adequate protection against Omicron
By Suzi Ring and BloombergDecember 23, 2021
Del-Kar Pharmacy owner Edwin Muldrow
HealthOne Chicago pharmacy avoids creating another drugstore desert by tapping into its deep roots
By Markian Hawryluk and Kaiser Health NewsDecember 22, 2021
HealthEU bulks up its arsenal against Omicron with approval of Novavax vaccine. Investors dump shares
By Christiaan HetznerDecember 20, 2021
Biogen headquarters
HealthBiogen slashes cost of Alzheimer’s drug by 50% six months after FDA approval
By Timothy Annett and BloombergDecember 20, 2021
Health‘Pharma Bro’ drugmaker will pay up to $40 million to settle case over jacking up medicine price by 4,000%
By The Associated PressDecember 8, 2021
MagazineInsulin’s deadly cost: Ultrahigh prices in the U.S. mean many diabetics can’t afford the medication they need to survive
By Geoff ColvinDecember 6, 2021
A health worker speaks with a patient in the reception area of a Testaro Covid-19 testing site in the Goodwood district of Cape Town, South Africa,
HealthOmicron vaccine to begin clinical trial in South Africa
By Jeremy KahnDecember 6, 2021
CommentaryIf we want the pandemic to end, CEOs need to do what governments won’t—including getting tougher and smarter about vaccines
By Mark Dybul and Serhat GümrükçüDecember 1, 2021
CommentaryThe most important meeting yet for global pandemic response—and drugmakers
By Nicole Hassoun and Kaushik BasuNovember 29, 2021
CommentaryTo avoid the superbug pandemic, we must fix the business model for new antibiotics
By Michelle McMurry-Heath and Henry SkinnerNovember 25, 2021
DeepMind and now Isomorphic Laboratories CEO Demis Hassabis
TechDeepMind spins out new Alphabet company focused on drug discovery
By Jeremy KahnNovember 4, 2021
FeaturesRiding high off vaccine wins, Pfizer CEO Albert Bourla delves into his strategy for the year ahead
By Erika FryOctober 30, 2021
COVID-19 experimental antiviral drug MOLNUPIRAVIR, two white pills with letters engraved on side, potential experimental WHO Coronavirus cure, pandemic outbreak crisis, isolated on blue background
HealthMerck says poorer countries can produce its new COVID pill without paying royalties
By David MeyerOctober 27, 2021
Robots work in a warehouse
NewslettersWhat’s big in A.I. this year
By Jeremy KahnOctober 12, 2021
1...
  • 23
  • 24
  • 25
  • 26
  • 27
...100
Most Popular
Personal Finance
The national debt isn't $39 trillion. One economist says it's actually $100 trillionAn image of a popular article
By Nick LichtenbergMarch 13, 2026
Success
When Jamie Dimon was fired from Citigroup, his daughters asked: 'Will we be homeless? Can I still go to college? Can I have your phone?'An image of a popular article
By Eleanor PringleMarch 13, 2026
North America
The U.S. Mint dropped the olive branch from the dime. What does that mean for the country?An image of a popular article
By Catherina GioinoMarch 12, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
Fortune Secondary Logo
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.